| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2014: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2013: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2012: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
To evaluate the efficacy of glypican-3 (GPC3) peptide vaccine therapy combined with chemotherapy, ovarian clear cell carcinoma (OCCC) patients with residual tumor after initial treatment were enrolled in our clinical trial. Seven OCCC patients were received GPC3-derived peptide vaccine combined with chemotherapy.
Immunological responses were analyzed by ex vivo IFN-γ enzyme-linked immunospot assay. In three out of four evaluable patients, the frequency of GPC3 peptide-specific CTLs after vaccination was slightly larger than that before vaccination. Concurrent standard-dose chemotherapy may impair GPC3 peptide vaccine-induced immunity.
Moreover, we established several HLA-A24-restricted GPC3 peptide-specific CTL clones from peripheral blood mononuclear cells of two out of nine patients vaccinated with GPC3 peptide by single cell sorting using Dextramer antibody.
|
